Capoluongo Ettore, Nardelli Carmela, Esposito Maria Valeria, Buonomo Antonio Riccardo, Gelzo Monica, Pinchera Biagio, Zappulo Emanuela, Viceconte Giulio, Portella Giuseppe, Setaro Mario, Gentile Ivan, Castaldo Giuseppe
Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, Napoli, Italy.
CEINGE Biotecnologie Avanzate S.C.a R.L., Napoli, Italy.
Front Oncol. 2021 Jul 20;11:705948. doi: 10.3389/fonc.2021.705948. eCollection 2021.
We report the case of a woman with non-Hodgkin lymphoma who remained positive on the molecular assay for SARS-CoV-2 for six months: she has never experienced a severe form of COVID-19 although in absence of seroconversion.
The whole SARS-CoV-2 genome analysis was performed by the CleanPlex SARS-CoV-2 Research and Surveillance NGS Panel (PARAGON GENOMICS, Hayward, USA).
We found twenty-two mutations in SARS-CoV-2 genome and a novel deleterious ORF3a frameshift c.766_769del corresponding to a unique and novel lineage. The region affected by this frameshift variant is reported as being important in determining SARS-CoV-2 immunogenicity. Patient's immunophenotype showed the absence of B lymphocytes and significantly reduced T-cell count. Only after the treatment with hyperimmune plasma she finally became negative on the swab.
Our findings could be helpful in the management of patients with immunodeficiency, particularly when novel variants, potentially altering the virus immune response, are present.
我们报告了一例非霍奇金淋巴瘤女性患者，其SARS-CoV-2分子检测持续六个月呈阳性：尽管未发生血清转化，但她从未经历过重症COVID-19。
采用CleanPlex SARS-CoV-2研究与监测二代测序 panel（PARAGON GENOMICS，美国海沃德）进行SARS-CoV-2全基因组分析。
我们在SARS-CoV-2基因组中发现了22个突变，以及一个新的有害ORF3a移码突变c.766_769del，对应一个独特的新谱系。据报道，受此移码变异影响的区域在决定SARS-CoV-2免疫原性方面很重要。患者的免疫表型显示缺乏B淋巴细胞且T细胞计数显著降低。仅在接受超免疫血浆治疗后，她的拭子检测最终转为阴性。
我们的发现可能有助于免疫缺陷患者的管理，特别是当存在可能改变病毒免疫反应的新变体时。
